The Integrow website mentions ClinicalTrials.gov NCT06662526, titled “Lithium for Prevention of Cognitive Decline and Neurodegeneration in Older Adults with Mild Cognitive Impairment.” This underscores that while preclinical and pilot human data are promising, large-scale confirmatory clinical trials are still in progress for low-dose lithium’s effects on cognition. This is not a trial specifically on the Re-Mind formulation itself, but on the key active ingredient.